{"id":2725,"date":"2025-03-18T11:42:51","date_gmt":"2025-03-18T11:42:51","guid":{"rendered":"https:\/\/genosophy.gr\/product\/anoia-kai-nosos-altsxaimer\/"},"modified":"2025-04-24T13:33:53","modified_gmt":"2025-04-24T13:33:53","slug":"anoia-kai-nosos-altsxaimer","status":"publish","type":"product","link":"https:\/\/genosophy.gr\/en\/product\/anoia-kai-nosos-altsxaimer\/","title":{"rendered":"Dementia and Alzheimer’s Disease"},"content":{"rendered":"

Dementia encompasses a group of neurodegenerative disorders<\/strong>, with Alzheimer\u2019s disease (AD)<\/strong> and frontotemporal dementia (FTD)<\/strong> being among the most extensively studied. While most cases are sporadic<\/strong>, up to 40% of FTD cases<\/strong> and 1\u20135% of AD cases<\/strong> have a monogenic (inherited) basis<\/strong>.<\/p>\n

The GENOSOPHY\u00ae Genetic Test<\/strong> includes 61 genes<\/strong> associated with autosomal dominant<\/strong>, autosomal recessive<\/strong>, and mitochondrial forms<\/strong> of dementia, offering comprehensive genetic screening<\/strong> for diagnosis, prognosis, and family risk assessment.<\/p>\n

Conditions Covered by the Test<\/h3>\n
    \n
  • Alzheimer\u2019s disease (AD)<\/strong> \u2013 including detection of the APOE \u03b54 allele<\/strong> in homozygosity, which is associated with significantly increased risk for Alzheimer\u2019s disease<\/li>\n
  • Frontotemporal dementia (FTD)<\/strong><\/li>\n
  • Hereditary leukodystrophies<\/strong><\/li>\n
  • Amyotrophic lateral sclerosis (ALS)<\/strong> & other neurodegenerative disorders<\/strong><\/li>\n
  • Mitochondrial dementia syndromes<\/strong><\/li>\n<\/ul>\n

    Clinical Benefits<\/h3>\n

    Diagnosis<\/h4>\n
      \n
    • Detection of pathogenic variants<\/strong> linked to neurodegenerative conditions<\/li>\n
    • Differentiation between sporadic<\/strong> and hereditary<\/strong> forms of dementia<\/li>\n<\/ul>\n

      Prognosis<\/h4>\n
        \n
      • Risk assessment for Alzheimer\u2019s disease<\/strong> and FTD<\/strong><\/li>\n
      • Evaluation of potential disease progression<\/strong><\/li>\n<\/ul>\n

        Management<\/h4>\n
          \n
        • Guidance for personalized monitoring and management<\/strong> to slow disease progression<\/li>\n
        • Family genetic counseling<\/strong> and risk analysis for relatives<\/li>\n<\/ul>\n

          Testing Process<\/h4>\n
            \n
          1. Sample collection<\/strong> (blood or saliva)<\/li>\n
          2. Analysis of 61 genes<\/strong> related to dementia and Alzheimer\u2019s disease<\/li>\n
          3. Results delivered within ~5 weeks<\/strong><\/li>\n<\/ol>\n

            Consultation and interpretation<\/strong> of the genetic results by professors of the Medical School of the National and Kapodistrian University of Athens (NKUA)<\/strong> is available as a separate service.<\/p>\n

            Genes Included in the Genetic Panel<\/h3>\n

            ABCA7, APOE, APP, CHMP2B, CSF1R, FUS, GRN, IGHG3, MAPT,<\/strong>
            \nMT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6, MT-RNR1, MT-RNR2,<\/strong>
            \nMT-TA, MT-TC, MT-TD, MT-TE, MT-TG, MT-TH, MT-TI, MT-TK, MT-TL1, MT-TL2, MT-TM, MT-TN, MT-TP, MT-TQ, MT-TR, MT-TS1, MT-TS2, MT-TW, MT-TY, MT-TV,<\/strong>
            \nPSEN1, PSEN2, PRNP, RNF216*, SIGMAR1, SORL1, SNCA, STAG3, TARDBP*, TREM2, TUBA4A, UBQLN2, UBE3A*, VCP, ZNF655<\/strong><\/p>\n

            Note:<\/strong> In addition to sequencing all coding exons, the GENOSOPHY\u00ae genetic test also analyzes numerous non-coding variants<\/strong>, such as promoter regions<\/strong> and introns<\/strong>. Detection sensitivity for single nucleotide variants (SNVs)<\/strong>, indels<\/strong>, and copy number variants (CNVs)<\/strong> is >99%<\/strong>.
            \nSensitivity may be slightly lower for genes marked with an asterisk (*).<\/p>\n","protected":false},"excerpt":{"rendered":"

            Dementia encompasses a group of neurodegenerative disorders, with Alzheimer\u2019s disease (AD) and frontotemporal dementia (FTD) being among the most extensively studied. While most cases are sporadic, up to 40% of FTD cases and 1\u20135% of AD cases have a monogenic (inherited) basis. The GENOSOPHY\u00ae Genetic Test includes 61 genes associated with autosomal dominant, autosomal recessive, […]<\/p>\n","protected":false},"featured_media":2466,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[83],"product_tag":[],"class_list":{"0":"post-2725","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-neuro-ipiresies-gia-epaggelmaties-en","8":"first","9":"instock","10":"taxable","11":"shipping-taxable","12":"product-type-simple"},"acf":[],"_links":{"self":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product\/2725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media\/2466"}],"wp:attachment":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media?parent=2725"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_brand?post=2725"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_cat?post=2725"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_tag?post=2725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}